Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. The upgrade of Bayer Aktiengesellschaft to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. You can learn more about the Zacks Rank here > So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Over the past three months, the Zacks Consensus Estimate for the company has increased 3.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >.Įarnings Estimate Revisions for Bayer Aktiengesellschaftįor the fiscal year ending December 2022, this company is expected to earn $2.02 per share, which is a change of 4.7% from the year-ago reported number.Īnalysts have been steadily raising their estimates for Bayer Aktiengesellschaft. Bayer Aktiengesellschaft (XTRA:BAYN) completed the acquisition of Gloryfeel Gmbh on March 8, 2022. Deloitte provided sell side advisory services throughout the entire M&A process, in particular in preparation phase, due diligence and contract negotiations. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. Bayer Aktiengesellschaft (XTRA:BAYN) acquired Gloryfeel Gmbh on March 8, 2022. And investors' appreciation of this improving business trend should push the stock higher. Their bulk investment action then leads to price movement for the stock.įor Bayer Aktiengesellschaft, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. Most Powerful Force Impacting Stock Prices In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.Īs such, the Zacks rating upgrade for Bayer Aktiengesellschaft is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price. Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. The Zacks Consensus Estimate - the consensus of EPS estimates from the sell-side analysts covering the stock - for the current and following years is tracked by the system. The sole determinant of the Zacks rating is a company's changing earnings picture. (AskBio), a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies across different therapeutic areas. An upward trend in earnings estimates - one of the most powerful forces impacting stock prices - has triggered this rating change. Berlin, Germany, OctoBayer AG today announced the acquisition of Asklepios BioPharmaceutical, Inc. It is available here.īayer’s market shares rallied 3% Monday morning, according to the Reuters news article.īayer Weighs Glyphosate Alternatives Bayer to pull Glyphosate from U.S.Bayer Aktiengesellschaft (BAYRY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). Anderson also needs to consider how he will fund future drug discoveries at the pharmaceutical business, which would remain after a spinoff,” the article said. “If it offloads the Crop Science division, Bayer could indemnify the new owners against the cost of future litigation up to a certain point. Anderson was most recently the head of Roche’s pharmaceuticals division.Ī Reuters article published Monday morning says a decision by Anderson and team to sell the Crop Science division “would be tricky but bountiful” for Bayer. The new CEO, Bill Anderson, a native of Texas, joined Bayer in April and assumed leadership of the company on June 1. Now, five years later, Baumann retired at the end of May after a 35-year career with Bayer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |